AbbVie has put I-Mab out of its misery. More than a year after scrapping a pair of clinical trials, the Big Pharma has cut its ties to the anti-CD47 antibody lemzoparlimab altogether and deprived ...

I-Mab (NASDAQ:IMAB) said an arbitration tribunal awarded no damages to Tracon Pharmaceuticals (NASDAQ:TCON) related to a collaboration agreement but the company would have to pay part of Tracon's ...

A phase 2 trial of I-Mab’s olamkicept in ulcerative colitis patients has met its primary endpoint. The study provides early evidence that the IL-6 inhibitor improves outcomes including rectal bleeding ...

The Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, and data is expected in the early second half of 2025; a 40-patient dose ...

MAINZ, Germany & MUNICH--(BUSINESS WIRE)--BioNTech AG, a rapidly growing biotechnology company developing precise and individualized immunotherapies for the treatment of cancer and the prevention of ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." ...

Failing to maintain the MAB can lead to penalties, which could range from monthly maintenance fees to, in some cases, account closure. (Image: Freepik) The Monthly Average Balance (MAB) is the average ...